A securities fraud lawsuit against Humana Inc. and its former CEO and CFO is proceeding after a judge ruled key claims valid. The lawsuit alleges that from July 2022 to October 2024, Humana misled investors about rising healthcare utilization costs, causing its stock to trade at inflated prices. When the truth emerged in October 2024, the stock fell 22%, and insiders had sold over $104 million in shares during the period. Current shareholders may have legal options as investigations into potential wrongdoing by company officers continue.
Humana's stock was upgraded to Outperform by Evercore ISI following strong Q2 2026 results. The company reported adjusted earnings of $7.61 per share and revenues of $40.9 billion, both exceeding analyst expectations, driven by a 20.7% growth in medi...
Humana reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $7.61 versus the expected $7.22, and revenue of $40.87 billion beating estimates. The company maintained its 2026 adjusted profit outlook ...
Humana reported a second-quarter net income of $694 million, driven by a surge in Medicare Advantage enrollees to 7.1 million, up from 5.8 million a year ago. Despite rising medical costs industry-wide, Humana managed to keep its benefit ratio at 91....
This week, U.S. markets focus on the Federal Reserve's July meeting, key inflation data like Core PCE, and second-quarter GDP figures, alongside major tech earnings from Microsoft, Meta, Apple, and Amazon. Rising oil prices and geopolitical tensions ...
